PharmGen Science, Inc. (004720.KS)
KRW 4035.0
(0.62%)
KRW 4035.0
(0.62%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 87.07 Billion KRW | 17.95% |
| 2022 | 73.81 Billion KRW | 12.29% |
| 2021 | 65.74 Billion KRW | 21.63% |
| 2020 | 54.04 Billion KRW | 9.85% |
| 2019 | 49.2 Billion KRW | 19.38% |
| 2018 | 41.21 Billion KRW | 16.95% |
| 2017 | 35.24 Billion KRW | 0.28% |
| 2016 | 35.14 Billion KRW | 26.26% |
| 2015 | 27.83 Billion KRW | 1.25% |
| 2014 | 27.48 Billion KRW | 8.29% |
| 2013 | 25.38 Billion KRW | 19.06% |
| 2012 | 21.32 Billion KRW | 22.83% |
| 2011 | 17.35 Billion KRW | -33.79% |
| 2010 | 26.21 Billion KRW | -6.7% |
| 2009 | 28.09 Billion KRW | 5.52% |
| 2008 | 26.62 Billion KRW | 4.44% |
| 2007 | 25.49 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 23.61 Billion KRW | 4.04% |
| 2024 Q1 | 22.7 Billion KRW | -0.66% |
| 2023 Q4 | 22.85 Billion KRW | 198.73% |
| 2023 Q1 | 19.87 Billion KRW | 0.35% |
| 2023 Q2 | 22.45 Billion KRW | 12.95% |
| 2023 Q3 | -23.14 Billion KRW | -203.1% |
| 2023 FY | 87.07 Billion KRW | 17.95% |
| 2022 Q4 | 19.8 Billion KRW | 6.47% |
| 2022 Q3 | 18.6 Billion KRW | 3.08% |
| 2022 Q2 | 18.04 Billion KRW | 3.96% |
| 2022 Q1 | 17.36 Billion KRW | 2.11% |
| 2022 FY | 73.81 Billion KRW | 12.29% |
| 2021 Q3 | 14.67 Billion KRW | -27.89% |
| 2021 Q2 | 20.34 Billion KRW | 48.3% |
| 2021 Q1 | 13.71 Billion KRW | -17.83% |
| 2021 FY | 65.74 Billion KRW | 21.63% |
| 2021 Q4 | 17 Billion KRW | 15.87% |
| 2020 Q2 | 11.52 Billion KRW | -11.68% |
| 2020 FY | 54.04 Billion KRW | 9.85% |
| 2020 Q4 | 16.69 Billion KRW | 29.67% |
| 2020 Q3 | 12.87 Billion KRW | 11.77% |
| 2020 Q1 | 13.04 Billion KRW | 2.86% |
| 2019 Q4 | 12.68 Billion KRW | 3.97% |
| 2019 Q2 | 12.56 Billion KRW | 6.89% |
| 2019 FY | 49.2 Billion KRW | 19.38% |
| 2019 Q1 | 11.75 Billion KRW | 7.6% |
| 2019 Q3 | 12.19 Billion KRW | -2.94% |
| 2018 Q4 | 10.92 Billion KRW | 0.7% |
| 2018 FY | 41.21 Billion KRW | 16.95% |
| 2018 Q2 | 9.57 Billion KRW | -2.84% |
| 2018 Q3 | 10.85 Billion KRW | 13.26% |
| 2018 Q1 | 9.85 Billion KRW | 4.82% |
| 2017 Q2 | 8.46 Billion KRW | -2.78% |
| 2017 FY | 35.24 Billion KRW | 0.28% |
| 2017 Q4 | 9.4 Billion KRW | 8.66% |
| 2017 Q3 | 8.65 Billion KRW | 2.23% |
| 2017 Q1 | 8.7 Billion KRW | -2.68% |
| 2016 Q1 | 8.48 Billion KRW | 5.47% |
| 2016 Q3 | 8.66 Billion KRW | -4.23% |
| 2016 Q4 | 8.94 Billion KRW | 3.33% |
| 2016 Q2 | 9.04 Billion KRW | 6.56% |
| 2016 FY | 35.14 Billion KRW | 26.26% |
| 2015 Q4 | 8.04 Billion KRW | 15.85% |
| 2015 FY | 27.83 Billion KRW | 1.25% |
| 2015 Q3 | 6.94 Billion KRW | 8.97% |
| 2015 Q2 | 6.37 Billion KRW | -1.44% |
| 2015 Q1 | 6.46 Billion KRW | -13.44% |
| 2014 Q3 | 7.17 Billion KRW | 9.52% |
| 2014 Q2 | 6.55 Billion KRW | 4.26% |
| 2014 FY | 27.48 Billion KRW | 8.29% |
| 2014 Q1 | 6.28 Billion KRW | -1.03% |
| 2014 Q4 | 7.47 Billion KRW | 4.08% |
| 2013 Q3 | 6.72 Billion KRW | 1.74% |
| 2013 Q4 | 6.35 Billion KRW | -5.59% |
| 2013 FY | 25.38 Billion KRW | 19.06% |
| 2013 Q1 | 5.71 Billion KRW | -32.27% |
| 2013 Q2 | 6.61 Billion KRW | 15.66% |
| 2012 Q4 | 8.44 Billion KRW | 67.6% |
| 2012 FY | 21.32 Billion KRW | 22.83% |
| 2012 Q2 | 4.2 Billion KRW | -5.02% |
| 2012 Q3 | 5.03 Billion KRW | 19.71% |
| 2012 Q1 | 4.43 Billion KRW | 99.96% |
| 2011 Q1 | 3.86 Billion KRW | -32.39% |
| 2011 Q4 | 2.21 Billion KRW | -12.79% |
| 2011 FY | 17.35 Billion KRW | -33.79% |
| 2011 Q2 | 8.81 Billion KRW | 128.23% |
| 2011 Q3 | 2.54 Billion KRW | -71.19% |
| 2010 Q3 | 5.15 Billion KRW | -29.73% |
| 2010 Q2 | 7.33 Billion KRW | -8.57% |
| 2010 Q1 | 8.01 Billion KRW | 42.13% |
| 2010 FY | 26.21 Billion KRW | -6.7% |
| 2010 Q4 | 5.71 Billion KRW | 10.95% |
| 2009 Q2 | 7.86 Billion KRW | 12.86% |
| 2009 Q4 | 5.64 Billion KRW | -26.04% |
| 2009 Q3 | 7.62 Billion KRW | -2.99% |
| 2009 Q1 | 6.96 Billion KRW | 0.11% |
| 2009 FY | 28.09 Billion KRW | 5.52% |
| 2008 Q1 | 6.6 Billion KRW | 2.61% |
| 2008 Q3 | 6.42 Billion KRW | -3.12% |
| 2008 Q4 | 6.95 Billion KRW | 8.28% |
| 2008 FY | 26.62 Billion KRW | 4.44% |
| 2008 Q2 | 6.63 Billion KRW | 0.36% |
| 2007 Q4 | 6.44 Billion KRW | -1.12% |
| 2007 Q2 | 6.35 Billion KRW | 2.66% |
| 2007 FY | 25.49 Billion KRW | 0.0% |
| 2007 Q3 | 6.51 Billion KRW | 2.57% |
| 2007 Q1 | 6.18 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Daewoong Co., Ltd. | 728.62 Billion KRW | 88.05% |
| Wooridul Huebrain Limited | 13.92 Billion KRW | -525.348% |